Intelligent drug delivery in personalized medicine: Multi-omics insights, digital simulation, and ai-driven formulation strategies: An illustration
Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai – 600125.
Review
Open Access Research Journal of Biology and Pharmacy, 2026, 16(02), 016-026.
Article DOI: 10.53022/oarjbp.2026.16.2.0020
Publication history:
Received on 09 January 2026; revised on 06 March 2026; accepted on 09 March 2026
Abstract:
Personalized medicine is rapidly evolving from a genomics-driven concept into a fully integrated bio-digital ecosystem that continuously adapts to the changing physiology of each individual. This manuscript presents a comprehensive overview of this transition, highlighting how multi-omics profiling, AI-powered simulations, intelligent drug delivery platforms, and adaptive regulatory frameworks collectively redefine modern healthcare. Multi-omics technologies spanning genomics, proteomics, metabolomics, exposomics, and microbiome analytics now enable high-resolution mapping of biological rhythms, environmental influences, and host–microbe interactions, offering a deeper and more dynamic understanding of disease susceptibility. Parallel advances in digital twin technology allow the creation of virtual replicas of individual organ systems capable of predicting disease progression, optimizing therapy, and supporting AI-generated synthetic control arms in clinical trials. On the therapeutic front, precision is further enhanced by stimuli-responsive nanocarriers, nanotheranostic systems, logic-gated biomaterials, and biofeedback-driven drug delivery devices that autonomously adjust treatment based on real-time biomarker fluctuations. AI-based formulation tools, excipient-interaction predictors, and personalized ADMET modelling expand the scope of individualized therapy, while 3D/4D-printing technologies enable on-demand, patient-specific dosage forms and micro-dosing strategies. The manuscript also examines global regulatory transformations by the FDA, EMA, PMDA, CDSCO, and NMPA, highlighting the shift toward biomarker-linked approvals, AI-supported diagnostics, companion-tool co-development, and adaptive pathways for highly stratified populations. Overall, this work synthesizes the biological, technological, and regulatory innovations driving personalized medicine into a proactive, predictive, and intelligent model of care one capable of tailoring interventions with unprecedented precision.
Keywords:
Personalized Medicine; Multi-Omics and Digital Twins; Stimuli-Responsive Nanotherapeutics; AI-Driven Formulation Science; Global Regulatory Frameworks
Full text article in PDF:
Copyright information:
Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0